RxDoctor Payments Data

Dawn Walston, APRN

Nurse Practitioner · Cape Girardeau, MONPI 1710061551

Payments from drug & device makers

$3,609in general payments, 2019–2025

Across 184 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$539
  • Novartis$526
  • Merck$440
  • Actelion Pharmaceuticals US, Inc.$308
  • Regeneron Healthcare Solutions, Inc.$265
  • Novo Nordisk$151
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,58999%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,609 in reported general payments places this provider in the 90th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$24,979
Medicare patients
264
Services billed
502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban34$21,739
EliquisApixaban33$20,455
EntrestoSacubitril/Valsartan16$10,417
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide11$578
Diltiazem 24hr Er (Cd)Diltiazem Hcl31$533
Carvedilol84$472
Losartan Potassium44$371
Ezetimibe29$321
Metoprolol Succinate63$317
Hydralazine Hcl54$261
Rosuvastatin Calcium14$251
Amlodipine Besylate52$237
Atorvastatin Calcium31$221
Amiodarone Hcl27$195
Chlorthalidone16$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$137$21,73934 claims
PfizerEliquis$34$20,45533 claims
NovartisEntresto$526$10,41716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Cape Girardeau

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →